(Total Views: 336)
Posted On: 11/14/2019 8:48:56 AM
Post# of 148936
Yeah, I believe you are correct. Lot of off-label in cancer, with NCCN recommendations. There is already some off-label with maraviroc as I posted about earlier.
I wonder how that fix that with the licensing deals? If they have one for HIV and a separate one for cancer. I suspect the cancer partner wouldn't like off-label sales going to the HIV partner. And it could become a considerable amount with more great cancer results in human trials.
I wonder how that fix that with the licensing deals? If they have one for HIV and a separate one for cancer. I suspect the cancer partner wouldn't like off-label sales going to the HIV partner. And it could become a considerable amount with more great cancer results in human trials.
(2)
(0)
Scroll down for more posts ▼